AstraZeneca's phase II trial results for its oral obesity drug, elecoglipron, indicate a substantial average weight reduction of 10.5% after 26 weeks, compared to a mere 0.6% for the placebo group. Notably, 88.8% of participants on the 75mg dose achieved at least 5% weight loss, a key clinical benchmark. The trial demonstrated that weight loss did not plateau, with reductions reaching 11.8% by 36 weeks. This sustained trajectory is expected to attract attention from investors and healthcare professionals, as it suggests potential long-term benefits in obesity management. AstraZeneca is now advancing elecoglipron into a phase III program, enhancing its cardiometabolic and kidney drug portfolio. This development positions AstraZeneca in direct competition with Eli Lilly's orforglipron, which has shown weight reductions between 8.6% and 12.6% over the same period. The oral GLP-1 market is highly anticipated, given the preference for oral medications over injections, marking a significant frontier in obesity treatment.